STAT+: Explaining Change Healthcare and the gravity of its cyberattack
The cyberattack on Change Healthcare has fractured the country’s health care payment infrastructure. But it…
Category: STAT+
STAT+: Medicare is a tricky market for telehealth companies. Why is Talkspace betting on it?
Over the last few years, virtual mental health company Talkspace has been on a relentless…
STAT+: Congress gives doctors Medicare pay bump, sets up December fight in new funding package
WASHINGTON — Doctors will get a 1.68% pay hike in Medicare starting March 9 under…
STAT+: RaDonda Vaught, nurse that accidentally killed patient, to speak at CommonSpirit event on patient safety
CommonSpirit Health is hosting an educational event this month featuring RaDonda Vaught, the Tennessee nurse…
STAT+: Many costly generic drugs are unavailable at Amazon, Cuban, and other alternative pharmacies
A growing number of alternative pharmacies — such as those run by Costco, Amazon, and…
STAT+: Federal judge rules against AstraZeneca in lawsuit challenging Medicare drug price negotiation
WASHINGTON — A federal judge in Delaware on Friday ruled against AstraZeneca in a case…
.jpg)
STAT+: Pharmalittle: We’re reading about RSV vax link to GSB, a Pfizer donation, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships
Oncology startup FogPharma just closed a $145 million Series E round, the company confirmed, reaching…
STAT+: Medical device lobby says it’s tired of waiting on Medicare to cover breakthrough devices
Medical technology lobby AdvaMed is fed up with the Centers for Medicare and Medicaid Services….
STAT+: Here are the cancer drugs Pfizer thinks could reignite investors’ interest
Pfizer spent more than four hours Thursday laying out its oncology program to investors. But…
STAT+: Change Healthcare cyber attack outage could persist for weeks, UnitedHealth Group executive implies
The outage caused by the Change Healthcare cyberattack could last weeks, a top UnitedHealth executive…
STAT+: What does America’s crackdown on Chinese firms mean for the U.S. biotech sector?
WASHINGTON — The federal government increasingly is scrutinizing Chinese businesses and their interactions with American…
STAT+: Pharmalittle: We’re reading about White House eyeing PBMs, Pfizer CEO’s frustrations, and more
Top of the morning to you, and a fine one it is. Cold winds and…
STAT+: Icon acquires HumanFirst to boost support for digital tools in clinical trials
As pharma companies wrestle with how and when to use wearables and other digital technologies…
This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act
Jean Cui, a former Pfizer chemist whose last company was sold to Bristol Myers Squibb…
STAT+: Biotech launches with $82 million for Parkinson’s cell therapy
The dream of being able to pluck a cell therapy off of a freezer shelf…
STAT+: Pfizer is about to make a big push in cancer. Will investors listen?
Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer…
STAT+: A ‘vaccine-like’ version of Wegovy is on the drawing board at Novo Nordisk
LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a…
STAT+: An inside look at PIPEs, the financing trend that has biotech abuzz
Biotech is awash in PIPEs. The numbers behind these privately negotiated purchases of public-company stock…
STAT+: White House to hold a listening session on reforming pharmacy benefit managers
In a bid to combat prescription drug costs, the White House will hold a listening…
STAT+: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines
One by one, the companies behind Zoloft, Prozac, and Paxil soured on psychiatry. It was…
STAT+: FTC says pharmacy benefit managers are stonewalling requests for information
A much-anticipated inquiry by U.S. antitrust regulators into pharmaceutical industry middlemen has been stymied because…
STAT+: Obesity drug from Viking Therapeutics hits target in Phase 2 study, raising hopes for a competitor to existing medicines
An obesity medication from Viking Therapeutics succeeded in a Phase 2 clinical study, the company…
STAT+: Experts say scale of Change cyberattack shows risk of centralized claims processing
Change Healthcare’s recent cyberattack has hospitals, doctors’ offices, and pharmacies across the country reeling as…
STAT+: MD Anderson tried — and failed — to resolve research credit dispute between two scientists, new documents show
Early last year, MD Anderson Cancer Center leadership had a problem on their hands: a…
STAT+: Congress ditches site-neutral hospital pay policy
WASHINGTON — Congress will not move forward with a controversial policy to equalize certain Medicare…
STAT+: Private equity firm offers $5.8 billion buyout of hospital billing company R1 RCM
R1 RCM, a large publicly traded technology company that helps hospitals and physicians collect money…
STAT+: The quest for psychedelics in the Amazon would push a Harvard botanist to his limits
The Aztecs called it teonanácatl, or “flesh of the Gods.” Some who ate the intoxicating…
STAT+: Congress punts on PBM reform efforts
WASHINGTON — Congress has abandoned its attempt to reform how pharmacy middlemen operate in an…
STAT+: Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH
LONDON — A drug in development as a weight loss treatment succeeded in a Phase…
STAT+: Liver disease MASH is next target for obesity drugs in development
As drugmakers race to join the obesity drug market ignited by the approval of Wegovy…
STAT+: Oregon suspends a portion of its drug transparency law found to be unconstitutional
In a victory for the pharmaceutical industry, Oregon officials have suspended a portion of a…
STAT+: Amgen’s rheumatoid arthritis drug Enbrel targeted for first-in-the-nation price limit in Colorado
WASHINGTON — Colorado is pioneering a new way for states to crack down on prescription…
STAT+: UnitedHealth cyberattack cripples pharmacies’ and hospitals’ ability to process insurance claims
Hospitals, pharmacies, and other health care providers are getting stuck in an insurance processing logjam…
STAT+: Pharmalittle: We’re reading about a pharma job slowdown, diet drugs boosting GDP, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Ocular Therapeutix moves in the right direction, and Alnylam tries to calm some nerves
This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes…
STAT+: Annovis Bio delivers candor on its Parkinson’s study, even if it doesn’t inspire much confidence
Annovis Bio had my biotech bull%^&! meter running red after it made a late change…
STAT+: Stump Pharmalot: An Ask Me Anything with Ed Silverman
In 2023, STAT launched a brand-new home for our subscribers to connect with each other…
STAT+: Clinical notes automation startup Abridge raises $150 million, takes aim at Microsoft Nuance
A Pittsburgh artificial intelligence startup emerging as a challenger to Microsoft’s clinical note taking business…
STAT+: FDA gives a mixed response to a petition seeking greater clinical trial transparency
The U.S. Food and Drug Administration told an advocacy group that it is not planning…
STAT+: San Diego biotech Neurocrine Biosciences joins PhRMA
WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying…
STAT+: Pharmalittle: We’re reading about India-made versions of Wegovy, an RSV vaccine scramble, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: Novavax and Gavi end a bitter dispute over Covid-19 vaccines with a refund up to $400 million
After a contentious dispute, Novavax has agreed to refund up to $400 million to the…
STAT+: Pharmalittle: We’re reading about a CEO change at AbbVie, a long-acting HIV drug, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: DarioHealth acquires Twill, hoping it’s a shortcut to profitability
DarioHealth, which makes apps for managing chronic diseases, today announced it will acquire digital mental…
STAT+: Hospitals race to adopt generative AI, even as regulators struggle to keep up with the risks
Usually the words generative AI in health are followed by a bold claim. The technology…
STAT+: Ring Therapeutics, a gene therapy startup, lays off 20% of staff
Ring Therapeutics, a gene therapy startup launched by Flagship Pioneering, has laid off just under…
STAT+: FDA warns medical device makers about rise in fabricated data
An increasing number of medical device companies are submitting fabricated and unreliable data, the Food…
STAT+: AbbVie CEO Gonzalez to step down after a decade fiercely defending its top seller, Humira
AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it…
STAT+: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more
Good morning, everyone, and welcome to another working week, which is getting off to a…